Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada

Vaccine. 2009 Nov 23;27(50):7105-9. doi: 10.1016/j.vaccine.2009.09.057. Epub 2009 Sep 26.


In the province of Quebec, Canada, the pneumococcal 7-valent conjugate vaccine (PCV-7) was licensed in 2001 and a publicly funded program was implemented in 2004, recommending 3 doses for healthy children. An economic analysis was performed both from a health care and societal perspective. Outcomes possibly prevented by PCV-7 and observed in 2006-2007 were compared to expected frequencies based on rates measured before PCV-7 use. Annual program costs were close to $21M for the health system and $23M for society. Approximately 20,000 infections were prevented annually and estimated economic benefits were $5M for the health system and $23M for society, using a 3% per annum discounting rate. The incremental cost-effectiveness ratio was $18,000 per QALY gained for the health system and the program was close to the break-even threshold in a societal perspective.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cost-Benefit Analysis
  • Health Care Costs*
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Humans
  • Immunization Programs / economics*
  • Models, Economic
  • Pneumococcal Infections / economics
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / economics*
  • Quality-Adjusted Life Years
  • Quebec
  • Vaccines, Conjugate / economics


  • Heptavalent Pneumococcal Conjugate Vaccine
  • Pneumococcal Vaccines
  • Vaccines, Conjugate